Skip to main content

Advertisement

SpringerLink
Log in

No association of MDM2 SNP309 with risk of glioblastoma and prognosis

  • Lab. Investigation-Human/Animal Tissue
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The MDM2 SNP309 variant has been shown to increase MDM2 expression and to be associated with tumor formation. In glioblastomas, the P53/MDM2 pathway is of crucial importance and MDM2 amplification is related to poor prognosis. However, we show here that MDM2 SNP309 is not associated with glioblastoma risk, and is not a prognostic factor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323–331

    Article  PubMed  Google Scholar 

  2. Sanson M, Thillet J, Hoang-Xuan K (2004) Molecular changes in gliomas. Curr Opin Oncol 16:607–613

    Article  PubMed  CAS  Google Scholar 

  3. Houillier C, Lejeune J, Benouaich-Amiel A, Laigle-Donadey F, Criniere E, Mokhtari K, Thillet J, Delattre JY, Hoang-Xuan K, Sanson M (2006) Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer 106:2218–2223

    Article  PubMed  CAS  Google Scholar 

  4. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602

    Article  PubMed  CAS  Google Scholar 

  5. Walsh CS, Miller CW, Karlan BY, Koeffler HP (2007) Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 104:660–664

    Article  PubMed  CAS  Google Scholar 

  6. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 24:4434–4440

    Article  PubMed  CAS  Google Scholar 

  7. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, Omata M (2006) MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12:4867–4871

    Article  PubMed  CAS  Google Scholar 

  8. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D (2005) The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65:9582–9587

    Article  PubMed  CAS  Google Scholar 

  9. Onat OE, Tez M, Ozcelik T, Toruner GA (2006) MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res 26:3473–3475

    PubMed  CAS  Google Scholar 

  10. Campbell IG, Eccles DM, Choong DY (2006) No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240:195–197

    Article  PubMed  CAS  Google Scholar 

  11. Millikan RC, Heard K, Winkel S, Hill EJ, Heard K, Massa B, Mayes L, Williams P, Holston R, Conway K, Edmiston S, de Cotret AR (2006) No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 15:175–177

    Article  PubMed  CAS  Google Scholar 

  12. Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B, Yulug IG (2006) Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 26:4975–4977

    PubMed  CAS  Google Scholar 

  13. Wilkening S, Bermejo JL, Burwinkel B, Klaes R, Bartram CR, Meindl A, Bugert P, Schmutzler RK, Wappenschmidt B, Untch M, Hemminki K, Forsti A (2006) The single nucleotide polymorphism IVS1 + 309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 66:646–648

    Article  PubMed  CAS  Google Scholar 

  14. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Jin G, Liu J, Wang X, Wei Q, Shen H (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240:261–267

    Article  PubMed  CAS  Google Scholar 

  15. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Jarvinen HJ, Mecklin JP, Atula T, Kontio R, Makitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA (2005) The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42:694–698

    Article  PubMed  CAS  Google Scholar 

  16. Pine SR, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, Shields PG, Harris CC (2006) MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 15:1559–1561

    Article  PubMed  CAS  Google Scholar 

  17. Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, Xu L, Wang X, Wei Q, Shen H (2006) Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 118:1275–1278

    Article  PubMed  CAS  Google Scholar 

  18. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119:718–721

    Article  PubMed  CAS  Google Scholar 

  19. Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q (2006) MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 27:2028–2033

    Article  PubMed  CAS  Google Scholar 

  20. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66:5104–5110

    Article  PubMed  CAS  Google Scholar 

  21. Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA, Gray HJ, Swisher EM (2007) Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46:239–247

    Article  PubMed  CAS  Google Scholar 

  22. Menin C, Scaini MC, De Salvo GL, Biscuola M, Quaggio M, Esposito G, Belluco C, Montagna M, Agata S, D’Andrea E, Nitti D, Amadori A, Bertorelle R (2006) Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 98:285–288

    Article  PubMed  CAS  Google Scholar 

  23. Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A, Meijers-Heijboer H, Schutte M (2006) MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat

  24. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ (2006) MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43:950–952

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Work supported by the Délégation à la Recherche Clinique (AP-HP; grant no MUL 03012).

Author information

Authors and Affiliations

  1. INSERM, U711, Biologie des Interactions Neurones & Glie, Paris, 75013, France

    Soufiane El Hallani, Yannick Marie, Ahmed Idbaih, Blandine Boisselier, Florence Laigle-Donadey, François Ducray, Jean-Yves Delattre & Marc Sanson

  2. Faculté de Médecine, Université Pierre et Marie Curie, Paris, 75013, France

    Soufiane El Hallani, Yannick Marie, Ahmed Idbaih, Blandine Boisselier, Florence Laigle-Donadey, François Ducray, Jean-Yves Delattre & Marc Sanson

  3. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie Mazarin, 47 boulevard de l’Hôpital, Paris, 75013, France

    Ahmed Idbaih, François Ducray, Jean-Yves Delattre & Marc Sanson

  4. Laboratoire d’Immunologie Cellulaire, INSERM U543, Paris, 75013, France

    Mathieu Rodero

Authors
  1. Soufiane El Hallani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yannick Marie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed Idbaih
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mathieu Rodero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Blandine Boisselier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Florence Laigle-Donadey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. François Ducray
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jean-Yves Delattre
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marc Sanson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Sanson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El Hallani, S., Marie, Y., Idbaih, A. et al. No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J Neurooncol 85, 241–244 (2007). https://doi.org/10.1007/s11060-007-9416-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-007-9416-1

Keywords

Search

Navigation